Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12...1011121314151617181920...2425»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Letermovir reduces the risk of CMV reactivation after allogeneic stem cell transplantation (A5) -  Sep 20, 2021 - Abstract #DGHO2021DGHO_416;    
    Although ganciclovir and valganciclovir are well known prophylaxis for CMV reactivation in solid-organ transplantation, the use of these drugs induces unacceptable side effects like myelosuppression in stem cell recipients...Letermovir was applied at a dose of 480 mg once a day or 240 mg once a day if cyclosporine was used as an initial immunosuppressive drug... The use of letermovir prophylaxis is associated with a significant lower risk of CMV reactivation after allogeneic stem cell transplantation.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Phase classification:  Letermovir for CMV Prevention After Lung Transplantation (clinicaltrials.gov) -  Sep 20, 2021   
    P2,  N=30, Not yet recruiting, 
    The use of letermovir prophylaxis is associated with a significant lower risk of CMV reactivation after allogeneic stem cell transplantation. Phase classification: P4 --> P2
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    [VIRTUAL] The significant drug-drug interaction between tacrolimus and letermovir in allogeneic hematopoietic stem cell transplantation recipients. (CHANNEL B) -  Sep 12, 2021 - Abstract #ICBMT2021ICBMT_303;    
    LET is classified as a weak-moderate CYP3A4 inhibitor and the reduction of LET dosage to half is recommended upon coadministration with cyclosporine...All patients received methotrexate at day1, 3, and 6 in combination with TAC for the prophylaxis of GVHD...Setting an appropriate TAC initial dosage can relieve the patient’s distress by reducing the frequency of blood sampling, while avoiding the complication from high TAC blood concentration such as thrombotic microangiopathy. Further studies in larger cohort are warranted.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Noxafil (posaconazole) / Merck (MSD)
    Pseudomelanosis Duodeni: A Rare and Incidental Endoscopic Finding (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_613;    
    His home medications included hydralazine, metoprolol, doxazosin, famciclovir, letermovir, atovaquone, posaconazole, prednisone, montelukast, and famotidine...His symptoms resolved after several days, and he was discharged on oral levofloxacin and vancomycin...Upper endoscopy demonstrates diffuse speckled dark pigmentation throughout the duodenal bulb (A). Histological examination of duodenal biopsies reveals pigment deposition within the lamina propria (B, hematoxylin and eosin stain) that stains negatively for iron (C, Prussian blue stain).
  • ||||||||||  Vistide (cidofovir) / Gilead
    Clinical, Review, Journal:  Small Molecules-Prospective Novel HCMV Inhibitors. (Pubmed Central) -  Aug 27, 2021   
    The list of novel small molecules that might have anti-HCMV activity has grown in recent years. In this short review, a selection of compounds in clinical trials and novel inhibitors targeting host-cell factors or viral proteins is presented, and their modes of action, described.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
    [VIRTUAL] CMV Prophylaxis for Allogeneic HSCT Patients (CHANNEL A) -  Jul 31, 2021 - Abstract #ICBMT2021ICBMT_83;    
    However, upon the approval of letermovir and reimbursement in Korea, diverse clinical situations such as CMV blips, and CMV testing methods should be clarified. In this talk, I would be discussing the practical points for CMV prophylaxis with letermovir based on the pivotal study analysis.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Letermovir for the compassionate therapeutic use of cytomegalovirus infection. (Pubmed Central) -  Jul 28, 2021   
    This study confirms efficacy and safety of LET for prophylaxis of CS-CMVi after alloHCT in a real-world setting, resulting in a significant patient benefit by reducing hospitalization needs and exposure to potentially toxic antiviral drugs for treatment of CMV reactivation. Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), PepVax (Tet-CMV) / Fortress, maribavir (TAK-620) / Takeda, GSK
    Review, Journal:  CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies. (Pubmed Central) -  Jul 27, 2021   
    The approval of the novel anti-CMV drug letermovir in 2017 has led to an increase in the use of antiviral prophylaxis as a preferred approach for prevention in many centers...Of the different CMV vaccine trials, PepVax has shown promising results in a phase 1 trial...Maribavir and adoptive T cell therapy are promising new therapies for treatment of CMV infections. CMV vaccine trials for prevention are also under way.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Journal:  Antiviral Drugs Against Herpesviruses. (Pubmed Central) -  Jul 15, 2021   
    The pyrophosphate analogue, foscarnet, and the nucleotide analogue, cidofovir, have been approved subsequently and constitute the second-line antiviral drugs...Recently, letermovir that targets the viral terminase complex was approved for the prophylaxis of human cytomegalovirus infections in hematopoietic stem cell transplant recipients. Other viral targets such as the protein kinase and the helicase-primase complex are also evaluated for the development of novel potent inhibitors against herpesviruses.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Observational data, Retrospective data, Journal:  Decrease in voriconazole concentration-to-dose ratio after letermovir initiation: a retrospective, observational study. (Pubmed Central) -  Jul 10, 2021   
    The percent change (-33.2%, p < 0.05) in the voriconazole concentration-to-dose ratio from periods A to C in the letermovir group was significantly lower than that in the control group. Therefore, frequent therapeutic drug monitoring of voriconazole concentrations and subsequent dose adjustments should be performed regularly in HSCT recipients.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical, Journal, Real-world evidence:  Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. (Pubmed Central) -  Jul 10, 2021   
    By comparing 114 patients who received LMV prophylaxis for a median 92 days to 571 patients without prophylaxis, we observed that prophylactic LMV could significantly (1) reduce the 180-day cumulative incidence of csCMV infection (44.7 vs. 72.4%, p < 0.001), (2) delay the median time until initiation of CMV antigenemia-guided preemptive therapy (90 vs. 36 days, p < 0.001), (3) shorten the duration of anti-CMV preemptive treatment (21 vs. 25 days, p = 0.006), and (4) improve the overall survival rate at 180 days after transplant (80.4 vs. 73.0%, p = 0.033) with a trend of lower non-relapse mortality (8.9 vs. 14.9%, p = 0.052). Our findings demonstrate that prophylactic LMV treatment is highly effective in preventing the development of csCMV infection and ultimately reduces transplant-related mortality.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Vistide (cidofovir) / Gilead, maribavir (TAK-620) / Takeda, GSK
    Clinical, Journal:  Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. (Pubmed Central) -  Jul 9, 2021   
    The investigational agent maribavir has shown promise as pre-emptive treatment; in patients with refractory or resistant disease the emergence of resistance while on treatment has been observed and ongoing studies will define efficacy in this population. Both agents have unique mechanisms of action limiting cross resistance, and neither exhibit myelotoxicity or nephrotoxicity.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical guideline:  Guidelines for Infection Prophylaxis, Monitoring and Therapy in Cord Blood Transplantation. (Pubmed Central) -  Jul 4, 2021   
    We review key concepts including the recent important role of letermovir in the prevention of CMV reactivation. In instances where there is a paucity of data, practice recommendations are provided, including the duration of antimicrobial prophylaxis.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Clinical, Journal:  Letermovir Prophylaxis Decreases Burden of CMV in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant. (Pubmed Central) -  Jun 24, 2021   
    Patients on LET PPX had fewer hospitalizations involving initiation of anti-CMV therapy compared to controls (0.93% vs 15.23%, respectively). Our analysis of the largest cohort of patients at high risk for CMV reactivation published to date demonstrates that letermovir prophylaxis significantly reduces the number of patients who receive CMV-active antiviral therapy for either DNAemia or disease due to CMV.